The company's goal is to globalise Stempeucel for Buerger's Disease and the market size is approximately $ 1.5 billion worldwide.

IIM Bengaluru announced that it would host the first India Conference on Innovation, Intellectual Property and Competition on December 7-8.

Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant for a consideration of $25,77...

Stempeutics has received process patent from the Japan for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia.

An orphan designation allows a company to benefit from incentives from the European Union to develop a medicine for a rare disease.

The ATMP classification, approved by the committee for Advanced Therapies (CAT) of the EMA will allow the Bengaluru- based Stempeutics to c...

Backed by the Manipal Education and Medical Group and drug maker Cipla, Stempeutics makes stem cell-based drugs or regenerative medicine.

Cipla's new initiative comes at a time when the company is making bold moves in expanding its international business.

ET delves into why one of India's oldest and best-known pharma companies is taking a hard look at itself.